May 2019- Kolkata, India

• Cordlife Sciences India Pvt. Ltd. has advanced in the Cord Blood Processing technology by introducing FDA- approved, cGTP and cGTP compliant AXP®II for the first time in India.

• The AXP®II System is a proprietary, automated system of Thermogenesis, for the isolation, collection, and storage of hematopoietic stem cell concentrates from cord blood.

ThermoGenesis is a wholly owned subsidiary of Cesca Therapeutics, the market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing as well.

As per Chris Xu, Ph.D., Chief Executive Officer of Cesca Therapeutics, since the introduction of AXP system in 2006, it has been viewed as the gold standard in the volume reduction processing of cord blood, and many of the world’s leading public and private cord blood banks are among their current long-time customers. He also added, “Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry. With AXP®II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK® software that together represent the biggest advancement in automated cord blood processing in many years. With the commercial launch of AXP® II, we are continuing to fulfill our commitment to provide the highest quality, most innovative products to the cord blood bank market.”

On the employment of the latest technology, Cordlife’s Chief Executive Officer, Upamannyue Roy Choudhury said “The decision to upgrade our cord blood processing technology to AXP®II, has majorly been based on our prerogative to always be at the forefront of science by adapting and offering the best advancements in processing and cryopreservation technologies to our clients. Because of the end of the day, it is the cell that matters to ensure a positive transplant outcome.”

AXP®II an automated, functionally closed, sterile platform that reduces a unit of cord blood to an accurate volume with precision, safety and confidence.” By adapting to AXP®II, Cordlife will now be able to offer its clients higher precision and higher MNC and CD34+ stem cell yield.
visit, https://www.cordlifeindia.com/

About Cordlife Group Limited

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a consumer healthcare group and one of the key providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife also expanded its presence in Myanmar and Vietnam to provide cord blood and cord lining banking services.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening, and family genetic screening services.

Quality and customer focus are amongst some of the cornerstones of Cordlife. The Group’s facilities in Singapore, Hong Kong, India, the Philippines and Malaysia are accredited by AABB, the organisation behind the world’s gold standard for cord blood banking. In addition, Cordlife Singapore and Healthbaby are accredited by FACT, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore and Healthbaby, two of just four cord blood banks in Asia, and seven in the world, to be accredited by both AABB and FACT concurrently. In the area of clinical diagnostics, Cordlife India, Healthbaby and Hong Kong Screening Centre are accredited by the College of American Pathologists (“CAP”). These quality achievements underpin the Group’s commitment to providing reliable healthcare solutions to have a better quality of life through innovation and technological advancement.

For more information, visit http://cordlife.listedcompany.com.


About Cordlife India

Cordlife India, headquartered in Kolkata, is a fully-owned subsidiary of Cordlife Group Limited. After a decade of operations since its launch in 2008, Cordlife India has emerged as the most premium brand amongst would-be parents and has expanded to over 200+ cities in India. From the 1st banked cord blood sample in 2008, Cordlife India currently enjoys the trust of over 75,000 parents and is growing on a daily basis.